This segment focuses on the development and commercialization of novel epigenetic therapies for various forms of cancer. Key activities include research and development of targeted treatments, clinical trials to evaluate efficacy and safety, and regulatory affairs to secure approvals for new therapies. The segment's lead product, Tazemetostat, targets EZH2, a protein involved in cancer development. The goal is to improve patient outcomes by providing personalized treatments that address the underlying genetic and epigenetic drivers of cancer. Future opportunities include expanding the use of Tazemetostat to other cancer types and developing new epigenetic inhibitors for different targets. This segment is crucial for Epizyme's mission of rewriting cancer treatment through transformative medicines.

This segment is dedicated to the discovery and development of novel epigenetic therapies. It involves identifying new drug targets, conducting preclinical studies, and advancing promising candidates into clinical trials. The segment leverages cutting-edge technologies in molecular biology, genomics, and bioinformatics to understand the role of epigenetic mechanisms in disease. Research and development activities include screening chemical libraries, optimizing drug candidates, and conducting in vitro and in vivo studies to assess efficacy and safety. The segment aims to create a pipeline of innovative epigenetic medicines that can address unmet medical needs in cancer and other diseases. Future opportunities include exploring new epigenetic targets and developing combination therapies that enhance the effectiveness of existing treatments.